ILMN Stock Falls -23% With A 10-day Losing Spree On Analyst Price Target Cuts
Illumina (ILMN) – a provider of sequencing and array-based genomic analysis solutions – hit a 10-day losing streak, with cumulative losses over this period amounting to -23%. The company’s market cap has crashed by about $5.5 Bil over the last 10 days and currently stands at $18 Bil.
The stock has YTD (year-to-date) return of 10.6% compared to 1.7% for S&P 500. This calls for a re-evaluation of the stock’s valuation to find out whether this is an opportunity or a trap.
What Triggered The Slide?
[1] JP Morgan Price Target Reduction
- Ulta Beauty Stock Down 24%,Time to Buy?
- The Bear Case: How FDX Behaves During Market Shocks
- The Bear Case: How MELI Behaves During Market Shocks
- Stress Testing STX: Historical Drawdowns and Macro Risks
- The Bear Case: How BX Behaves During Market Shocks
- The Bear Case: How AMT Behaves During Market Shocks
- JP Morgan’s Casey Woodring lowered the price target from $130 to $120
- Maintained a Neutral rating
- Impact: Sustained Institutional Selling, Negative Sentiment Amplifier
[2] Piper Sandler Price Target Reduction
- Piper Sandler’s David Westenberg lowered the price target from $195 to $170
- Maintained an Overweight rating despite the target cut
- Impact: Increased Investor Concern, Continuation of Downtrend
Opportunity or Trap?
Below is our take on valuation.
There are a few things to fear in ILMN stock given its overall Moderate operating performance and financial condition. This is aligned with the stock’s Moderate valuation because of which we think it is Fairly Priced (For details, see Buy or Sell ILMN).
But here is the real interesting point.
You are reading about this -23% move after it happened. The market has already priced in the news. To avoid the next loser before the headlines, you need predictive signals, not notifications. Our High Quality Portfolio has a risk model designed to reduce exposure to losers.
Returns vs S&P 500
The following table summarizes the return for ILMN stock vs. the S&P 500 index over different periods, including the current streak:
| Return Period | ILMN | S&P 500 |
|---|---|---|
| 1D | -2.1% | 0.5% |
| 10D (Current Streak) | -23.4% | 0.2% |
| 1M (21D) | -19.6% | 0.6% |
| 3M (63D) | -3.2% | 3.6% |
| YTD 2026 | -10.6% | 1.7% |
| 2025 | -1.8% | 16.4% |
| 2024 | -1.2% | 23.3% |
| 2023 | -31.1% | 24.2% |
Take a look at what history tells you about whether past dips like this have been buying opportunities or traps: ILMN Dip Buyer Analysis.
Gains and Losses Streaks: S&P 500 Constituents
There are currently 66 S&P constituents with 3 days or more of consecutive gains and 25 constituents with 3 days or more of consecutive losses.
| Consecutive Days | # of Gainers | # of Losers |
|---|---|---|
| 3D | 26 | 17 |
| 4D | 19 | 1 |
| 5D | 12 | 3 |
| 6D | 6 | 3 |
| 7D or more | 3 | 1 |
| Total >=3 D | 66 | 25 |
Key Financials for Illumina (ILMN)
Last 2 Fiscal Years:
| Metric | FY2023 | FY2024 |
|---|---|---|
| Revenues | $4.5 Bil | $4.4 Bil |
| Operating Income | $-222.0 Mil | $600.0 Mil |
| Net Income | $-1.2 Bil | $-1.2 Bil |
Last 2 Fiscal Quarters:
| Metric | 2025 FQ2 | 2025 FQ3 |
|---|---|---|
| Revenues | $1.1 Bil | $1.1 Bil |
| Operating Income | $214.0 Mil | $227.0 Mil |
| Net Income | $235.0 Mil | $150.0 Mil |
The losing streak ILMN stock is currently on doesn’t inspire much confidence among investors. In contrast, Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 — the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics.